

7

WST93AUSA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICES

Assistant Commissioner for Patents Washington, DC 20231

AMENDMENT AND STATEMENT PURSUANT TO 37 CFR §1.821(f) and (g)

Pursuant to the attached notice received from the U.S. Patent and Trademark Office that the computer-readable diskette containing the "Sequence Listing" as submitted does not comply with the requirements of 37 CFR §1.822 and/or 1.832, Applicants herewith submit a substitute Sequence Listing in computer readable form and a substitute paper copy of the Sequence Listing as required by 37 CFR §1.821-1.825.

Please enter the substitute computer readable form and attached substitute paper copy of the Sequence Listing into this application.

EXPRESS MAIL NO. ET 033633632 US

As required by 37 CFR §1.821(f), this statement affirms that to the best of my knowledge and belief that the Sequence Listing information recorded in the substitute computer readable form is identical to the substitute paper copy of the Sequence Listing. As required by 37 CFR §1.821(g), this statement affirms that to the best of my knowledge and belief this substitute Sequence Listing presents no new matter to the application as filed.

Respectfully submitted,

HOWSON AND HOWSON Attorneys for the Applicants

By Mary E. Bak

Registration No. 31,215


Spring House Corporate Center

Box 457

Spring House, PA 19477

(215) 540-9200

RAW SEQUENCE LISTING ERROR REPORT



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/83/.047Source: 9/83/.047Date Processed by STIC: 9/21/2001

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216. PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax) PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE <u>CHECKER</u> <u>VERSION 3.0 PROGRAM</u>, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW:

Checker Version 3.0

The Checker Version 3.0 application is a state-of the-art Windows based software program employing a logical and intuitive user-interface to check whether a sequence listing is in compliance with format and content rules. Checker Version 3.0 works for sequence listings generated for the original version of 37 CFR §§1.821 – 1.825 effective October 1, 1990 (old rules) and the revised version (new rules) effective July 1, 1998 as well as World Intellectual Property Organization (WIPO) Standard ST.25.

Checker Version 3.0 replaces the previous DOS-based version of Checker, and is Y2K-compliant. Checker allows public users to check sequence listings in Computer Readable form (CRF) before submitting them to the United States Patent and Trademark Office (USPTO). Use of Checker prior to filing the sequence listing is expected to result in fewer errored sequence listings, thus saving time and money.

Checker Version 3.0 can be down loaded from the USPTO website at the following address: http://www.uspto.gov/web/offices/pac/checker

Rate Sequence Listing Error Summary

SERIAL NUMBER: _O 9/ ERROR DETECTED SUGGESTED CORRECTION ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE Wrapped Nucleics The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will Wrapped Aminos prevent "wrapping." Invalid Line Length The rules require that a line not exceed 72 characters in length. This includes white spaces. The numbering under each 5th amino acid is misaligned. Do not use tab codes between numbers; Misaligned Amino use space characters, instead. Numbering The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please Non-ASCII ensure your subsequent submission is saved in ASCII text. Sequence(s) contain n's or Xaa's representing more than one residue. Per Sequence Rules, Variable Length each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing. A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid PatentIn 2.0 Normally, PatentIn would automatically generate this section from the "bug" previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences. missing. If intentional, please insert the following lines for each skipped sequence: Sequence(s) Skipped Sequences (2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) (OLD RULES) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading) (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) This sequence is intentionally skipped Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences. missing. If intentional, please insert the following lines for each skipped sequence. Skipped Sequences Sequence(s) <210> sequence id number (NEW RULES) <400> sequence id number 000 Use of n's and/or Xaa's have been detected in the Sequence Listing. Use of n's or Xaa's Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present. (NEW RULES) In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents. Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or 10 Invalid <213> scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or Response is Artificial Sequence missing the <220> "Feature" and associated numeric identifiers and responses. Use of <220>Sequence(s) Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section. (See 'Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules) Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, PatentIn 2.0 12 resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence "bug" listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.

AMC - Biotechnology Systems Branch - 06/04/2001



RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/831,047

DATE: 05/21/2001 TIME: 08:40:08

Input Set : A:\sequencelst.txt

Output Set: N:\CRF3\05212001\I831047.raw

```
Does Not Comply
     4 <110> APPLICANT: The Wistar Institute of Anatomy and Biology
                                                                        Corrected Diskette Needed
             The Trustees of the University of Pennsylvania
             Blaszczyk-Thurin, Magdalena
             Kieber-Emmons, Thomas
    9 <120> TITLE OF INVENTION: Compositions and Methods For Treatment of Cancer
   11 <130> FILE REFERENCE: WST93PCT
--> 13 <140> CURRENT APPLICATION NUMBER: US/09/831,047
--> 14 <141> CURRENT FILING DATE: 2001-05-03
   16 <150> PRIOR APPLICATION NUMBER: 60/107,478
   17 <151> PRIOR FILING DATE: 1998-11-06
   19 <160> NUMBER OF SEQ ID NOS: 121
   21 <170> SOFTWARE: PatentIn Ver. 2.0
   23 <210> SEQ ID NO: 1
   24 <211> LENGTH: 12
   25 <212> TYPE: PRT
   26 <213> ORGANISM: Artificial Sequence
   28 <220> FEATURE:
   29 <223> OTHER INFORMATION: Description of Artificial Sequence:
             peptido-mimetic of a Lewis antigen
   32 <400> SEQUENCE: 1
   33 Asp Leu Trp Asp Trp Val Val Gly Lys Pro Ala Gly
   34
        1
   37 <210> SEQ ID NO: 2
   38 <211> LENGTH: 12
   39 <212> TYPE: PRT
   40 <213> ORGANISM: Artificial Sequence
   42 <220> FEATURE:
   43 <223> OTHER INFORMATION: Description of Artificial Sequence:
            peptido-mimetic of a Lewis antigen
   44
   46 <400> SEQUENCE: 2
   47 Asp Ala Trp Asp Trp Val Val Gly Lys Pro Ala Gly
   48
   51 <210> SEQ ID NO: 3
   52 <211> LENGTH: 12
   53 <212> TYPE: PRT
   54 <213> ORGANISM: Artificial Sequence
   56 <220> FEATURE:
   57 <223> OTHER INFORMATION: Description of Artificial Sequence:
            peptido-mimetic of a Lewis antigen
   60 <400> SEQUENCE: 3
   61 Asp Asp Trp Asp Trp Val Val Gly Lys Pro Ala Gly
   62
        1
   65 <210> SEQ ID NO: 4
   66 <211> LENGTH: 12
   67 <212> TYPE: PRT
   68 <213> ORGANISM: Artificial Sequence
```

70 <220> FEATURE:

RAW SEQUENCE LISTING DATE: 05/21/2001 PATENT APPLICATION: US/09/831,047 TIME: 08:40:08

Input Set : A:\sequencelst.txt

Output Set: N:\CRF3\05212001\I831047.raw

```
71 <223> OTHER INFORMATION: Description of Artificial Sequence:
         peptido-mimetic of a Lewis antigen
74 <400> SEQUENCE: 4
75 Asp Tyr Trp Asp Trp Val Val Gly Lys Pro Ala Gly
                     5
                                        10
76
   1
79 <210> SEQ ID NO: 5
80 <211> LENGTH: 12
81 <212> TYPE: PRT
82 <213> ORGANISM: Artificial Sequence
84 <220> FEATURE:
85 <223> OTHER INFORMATION: Description of Artificial Sequence:
         peptido-mimetic of a Lewis antigen
88 <400> SEQUENCE: 5
89 Asp Glu Trp Asp Trp Val Val Gly Lys Pro Ala Gly
                                         10
90
     1
93 <210> SEQ ID NO: 6
94 <211> LENGTH: 12
95 <212> TYPE: PRT
96 <213> ORGANISM: Artificial Sequence
98 <220> FEATURE:
99 <223> OTHER INFORMATION: Description of Artificial Sequence:
          peptido-mimetic of a Lewis antigen
100
102 <400> SEQUENCE: 6
103 Asp Lys Trp Asp Trp Val Val Gly Lys Pro Ala Gly
104 1
107 <210> SEQ ID NO: 7
108 <211> LENGTH: 12
109 <212> TYPE: PRT
110 <213> ORGANISM: Artificial Sequence
112 <220> FEATURE:
113 <223> OTHER INFORMATION: Description of Artificial Sequence:
          peptido-mimetic of a Lewis antigen
114
116 <400> SEQUENCE: 7
117 Asp Arg Trp Asp Trp Val Val Gly Lys Pro Ala Gly
                                          10
118
      1
121 <210> SEQ ID NO: 8
122 <211> LENGTH: 12
123 <212> TYPE: PRT
124 <213> ORGANISM: Artificial Sequence
126 <220> FEATURE:
127 <223> OTHER INFORMATION: Description of Artificial Sequence:
          peptido-mimetic of a Lewis antigen
130 <400> SEQUENCE: 8
131 Asp Ser Trp Asp Trp Val Val Gly Lys Pro Ala Gly
132
135 <210> SEQ ID NO: 9
136 <211> LENGTH: 12
137 <212> TYPE: PRT
138 <213> ORGANISM: Artificial Sequence
```



RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/831,047

DATE: 05/21/2001 TIME: 08:40:08

Input Set : A:\sequencelst.txt

Output Set: N:\CRF3\05212001\1831047.raw

140 <220> FEATURE: 141 <223> OTHER INFORMATION: Description of Artificial Sequence: peptido-mimetic of a Lewis antigen 144 <400> SEQUENCE: 9 145 Asp Leu His Asp Trp Val Val Gly Lys Pro Ala Gly 146 1 10 149 <210> SEQ ID NO: 10 150 <211> LENGTH: 12 151 <212> TYPE: PRT 152 <213> ORGANISM: Artificial Sequence 154 <220> FEATURE: 155 <223> OTHER INFORMATION: Description of Artificial Sequence: 156 peptido-mimetic of a Lewis antigen 158 <400> SEQUENCE: 10 159 Asp Leu Tyr Asp Trp Val Val Gly Lys Pro Ala Gly 160 1 5 10 163 <210> SEQ ID NO: 11 164 <211> LENGTH: 12 165 <212> TYPE: PRT 166 <213> ORGANISM: Artificial Sequence 168 <220> FEATURE: 169 <223> OTHER INFORMATION: Description of Artificial Sequence: peptido-mimetic of a Lewis antigen 170 172 <400> SEQUENCE: 11 173 Asp Leu Phe Asp Trp Val Val Gly Lys Pro Ala Gly 174 1 10 177 <210> SEQ ID NO: 12 178 <211> LENGTH: 12 179 <212> TYPE: PRT 180 <213> ORGANISM: Artificial Sequence 182 <220> FEATURE: 183 <223> OTHER INFORMATION: Description of Artificial Sequence: peptido-mimetic of a Lewis antigen 184186 <400> SEQUENCE: 12 187 Asp Leu Met Asp Trp Val Val Gly Lys Pro Ala Gly 188 1 10 191 <210> SEQ ID NO: 13 192 <211> LENGTH: 12 193 <212> TYPE: PRT 194 <213> ORGANISM: Artificial Sequence 196 <220> FEATURE: 197 <223> OTHER INFORMATION: Description of Artificial Sequence: peptido-mimetic of a Lewis antigen 198 200 <400> SEQUENCE: 13 201 Asp Leu Ala Asp Trp Val Val Gly Lys Pro Ala Gly 202 10 205 <210> SEQ ID NO: 14 206 <211> LENGTH: 12 207 <212> TYPE: PRT



RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/831,047

DATE: 05/21/2001 TIME: 08:40:08

Input Set : A:\sequencelst.txt

Output Set: N:\CRF3\05212001\I831047.raw

```
208 <213> ORGANISM: Artificial Sequence
  210 <220> FEATURE:
 211 <223> OTHER INFORMATION: Description of Artificial Sequence:
  212
           peptido-mimetic of a Lewis antigen
 214 <400> SEQUENCE: 14
 215 Asp Leu Glu Asp Trp Val Val Gly Lys Pro Ala Gly
 216 1
 219 <210> SEQ ID NO: 15
 220 <211> LENGTH: 12
 221 <212> TYPE: PRT
 222 <213> ORGANISM: Artificial Sequence
 224 <220> FEATURE:
 225 <223> OTHER INFORMATION: Description of Artificial Sequence:
           peptido-mimetic of a Lewis antigen
 228 <400> SEQUENCE: 15
 229 Asp Leu Asp Asp Trp Val Val Gly Lys Pro Ala Gly
 230 1
                       5
 233 <210> SEQ ID NO: 16
 234 <211> LENGTH: 12
 235 <212> TYPE: PRT
 236 <213> ORGANISM: Artificial Sequence
 238 <220> FEATURE:
 239 <223> OTHER INFORMATION: Description of Artificial Sequence:
 240
           peptido-mimetic of a Lewis antigen
242 <400> SEQUENCE: 16
243 Asp Leu Lys Asp Trp Val Val Gly Lys Pro Ala Gly
244 1
247 <210> SEQ ID NO: 17
248 <211> LENGTH: 12
249 <212> TYPE: PRT
250 <213> ORGANISM: Artificial Sequence
252 <220> FEATURE:
253 <223> OTHER INFORMATION: Description of Artificial Sequence:
254
          peptido-mimetic of a Lewis antigen
256 <400> SEQUENCE: 17
257 Asp Leu Arg Asp Trp Val Val Gly Lys Pro Ala Gly
258
     1
                                          10
261 <210> SEQ ID NO: 18
262 <211> LENGTH: 12
263 <212> TYPE: PRT
264 <213> ORGANISM: Artificial Sequence
266 <220> FEATURE:
267 <223> OTHER INFORMATION: Description of Artificial Sequence:
268
          peptido-mimetic of a Lewis antigen
270 <400> SEQUENCE: 18
271 Asp Leu Ser Asp Trp Val Val Gly Lys Pro Ala Gly
272
                                         10
275 <210> SEQ ID NO: 19
276 <211> LENGTH: 12
```

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/831,047

Input Set : A:\sequencelst.txt

Output Set: N:\CRF3\05212001\I831047.raw

DATE: 05/21/2001

TIME: 08:40:08

277 <212> TYPE: PRT 278 <213> ORGANISM: Artificial Sequence 280 <220> FEATURE: 281 <223> OTHER INFORMATION: Description of Artificial Sequence: peptido-mimetic of a Lewis antigen 282 284 <400> SEQUENCE: 19 285 Asp Leu Trp Glu Trp Val Val Gly Lys Pro Ala Gly 5 286 289 <210> SEQ ID NO: 20 290 <211> LENGTH: 12 291 <212> TYPE: PRT 292 <213> ORGANISM: Artificial Sequence 294 <220> FEATURE: 295 <223> OTHER INFORMATION: Description of Artificial Sequence: peptido-mimetic of a Lewis antigen 296 298 <400> SEQUENCE: 20 299 Asp Leu Trp Ser Trp Val Val Gly Lys Pro Ala Gly 10 300 1 303 <210> SEQ ID NO: 21 304 <211> LENGTH: 12 305 <212> TYPE: PRT 306 <213> ORGANISM: Artificial Sequence 308 <220> FEATURE: 309 <223> OTHER INFORMATION: Description of Artificial Sequence: peptido-mimetic of a Lewis antigen 312 <400> SEQUENCE: 21 313 Asp Leu Trp Pro Trp Val Val Gly Lys Pro Ala Gly 314 1 317 <210> SEQ ID NO: 22 318 <211> LENGTH: 12 319 <212> TYPE: PRT 320 <213> ORGANISM: Artificial Sequence 322 <220> FEATURE: 323 <223> OTHER INFORMATION: Description of Artificial Sequence: peptido-mimetic of a Lewis antigen 324 326 <400> SEQUENCE: 22 327 Asp Leu Trp Val Trp Val Val Gly Lys Pro Ala Gly 10 328 1 331 <210> SEQ ID NO: 23 332 <211> LENGTH: 12 333 <212> TYPE: PRT 334 <213> ORGANISM: Artificial Sequence 336 <220> FEATURE: 337 <223> OTHER INFORMATION: Description of Artificial Sequence: peptido-mimetic of a Lewis antigen 340 <400> SEQUENCE: 23 341 Asp Leu Trp Met Trp Val Val Gly Lys Pro Ala Gly 342 345 <210> SEQ ID NO: 24

09/831,047 6

sel item 9 on Eva Summary Sheet

FJI

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

VERIFICATION SUMMARY

DATE: 05/21/2001 PATENT APPLICATION: US/09/831,047 TIME: 08:40:09

Input Set : A:\sequencelst.txt

Output Set: N:\CRF3\05212001\I831047.raw

:13 M:270 C: Current Application Number differs, Replaced Application Number :14 M:271 C: Current Filing Date differs, Replaced Current Filing Date

:1419 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:100 :1419 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:100

:1419 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:100

:1573 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:111

:1573 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:111

:1573 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:111

:1587 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:112 :1587 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:112

:1587 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:112